









WHAT IS CLAIMED IS:


1. A method for treating ocular hypertension or glaucoma which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Table 1:
- 5
- Table 1














emindole DA




epi-emindole DA










emindole PA












emindole DB




emindole SB












Fumitremorgen A




Janthitrem B




Janthitrem C




Janthitrem E




Janthitrem F




Janthitrem G




Lolitre^m A




Lolitre^m B




Lolitre^m C








Lolitre^m E







Lolitre^m F



Lolitre^m H





or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer or mixture thereof.

2. The method according to Claim 1 wherein the compound of formula I is applied as a topical formulation.

3. The method according to claim 3 wherein the topical
5 formulation is a solution or suspension.

4. The method of Claim 3, which comprises administering a second active ingredient, concurrently or consecutively, wherein the second active ingredient is a hypotensive agent selected from a β -adrenergic blocking agent,
10 adrenergic agonist, a parasympathomimetic agent, a carbonic anhydrase inhibitor, EP4 agonist and a prostaglandin or a prostaglandin derivative.

5. The method according to claim 4 wherein the β -adrenergic blocking agent is timolol, levobunolol, carteolol, optipranolol, metapranolol or
15 betaxolol; the parasympathomimetic agent is pilocarpine, carbachol, or phospholine iodide; adrenergic agonist is iopidine, brimonidine, epinephrine, or dipivephrin, the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost or rescular, and the prostaglandin derivative is a hypotensive lipid derived from PGF 2α prostaglandins.

20 6. A method according to claim 2 in which the topical formulation contains xanthan gum or gellan gum.

7. A method for treating macular edema, macular degeneration,
25 for providing a neuroprotective effect, increasing retinal and optic nerve head blood velocity or increasing retinal and optic nerve oxygen tension which comprises administering to a patient in need of such treatment a pharmaceutically effective amount of a compound as recited in claim 1

8. The method according to Claim 7 wherein the compound of formula I is applied as a topical formulation in the form of a solution or suspension.

9. The method of Claim 8, which comprises administering a second active ingredient, concurrently or consecutively, wherein the second active
35 ingredient is a hypotensive agent selected from a β -adrenergic blocking agent,

adrenergic agonist, a parasympathomimetic agent, a carbonic anhydrase inhibitor, EP4 agonist and a prostaglandin or a prostaglandin derivative.

10. The method according to claim 9 wherein the β -adrenergic
5 blocking agent is timolol, levobunolol, carteolol, optipranolol, metapranolol or
betaxolol; the parasympathomimetic agent is pilocarpine, carbachol, or phospholine
iodide; adrenergic agonist is iopidine, brimonidine, epinephrine, or dipivephrin, the
carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or
brinzolamide; the prostaglandin is latanoprost or rescula, and the prostaglandin
10 derivative is a hypotensive lipid derived from PGF2 α prostaglandins.

11. A method according to claim 8 in which the topical formulation
contains xanthan gum or gellan gum.